FDA Approval for Tivicay

The Food & Drug Administration (FDA) has approved Tivicay (dolutegravir) for the treatment of HIV-1 infection.

The drug is an integrase strand transfer inhibitor that works by interfering with one of the enzymes necessary for HIV to multiply. This has a double-effect on the HIV:

  1. It reduces the amount of HIV-1 in the bloodstream (known as the viral load)
  2. It increases the amount of white blood cells, known as CD4+ cells, so that the individual’s immunity is increased 

These effects combined mean that a patient’s condition can be held at the HIV stage for as long as possible, thus delaying the onset of AIDS. 

Tivicay is not, however, a one-stop shop for sufferers; individuals will still need to take antiretroviral drugs to manage their HIV as well as any other medication that they may need to manage the symptoms of their condition. It’s main benefit is that it works in a novel way to current medications so is vitally important in the fight against this viral disease.

According to the Centres for Disease Control and Prevention, 50’000 new cases of HIV are diagnosed each year so finding new drugs to halt viral progression is a hot topic in the pharmaceutical world. 

To read more, try these links:




The above image shows a HIV-1 molecule and is supplied courtesy of Design Culture Lab http://www.designculturelab.org/2009/09/16/visualisation-materialisation-and-affect/hiv1-784396/


Tags: , , , ,

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: